ROCKET PHARMACEUTICALS INC (RCKT) competitors & alternatives
Health Care · NASDAQ
ROCKET PHARMACEUTICALS INC (RCKT)'s top competitors and alternatives — its most similar public companies — include Pfizer (PFE), Ultragenyx (RARE), BioMarin Pharmaceutical (BMRN), Biogen (BIIB), REGENXBIO INC (RGNX), PTC THERAPEUTICS INC (PTCT), Sarepta Therapeutics (SRPT), NOVARTIS AG (NVS), KRYSTAL BIOTECH INC (KRYS), EDITAS MEDICINE INC (EDIT), BEAM THERAPEUTICS INC (BEAM) and CAPRICOR THERAPEUTICS INC (CAPR). These are ROCKET PHARMACEUTICALS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top RCKT competitors & alternatives
-
PfizerPFEHealth Care
Global biopharmaceutical company discovering, developing, and manufacturing prescription medicines and vaccines across oncology, immunology, cardiovascular,…
$25.01 (as of 2026-07-23) · market cap $142.4B
-
UltragenyxRAREHealth Care
Ultragenyx is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for serious, rare, and ultra-rare genetic diseases.
$27.02 (as of 2026-07-23) · market cap $2.7B
-
BioMarin PharmaceuticalBMRNHealth Care
BioMarin is a global rare disease biotech company delivering genetic medicines across enzyme therapies, growth disorders, metabolic diseases, and gene…
$58.87 (as of 2026-07-23) · market cap $11.3B
-
BiogenBIIBHealth Care
Biogen is a global biotechnology company developing and commercializing therapies across neurology, immunology, and rare genetic disease.
$200.62 (as of 2026-07-23) · market cap $30.0B
-
REGENXBIO INCRGNXHealth Care
Clinical-stage gene therapy company using proprietary NAV vectors to deliver functional genes for rare genetic and retinal disorders through partnerships with…
$10.25 (as of 2026-07-23) · market cap $526M
-
PTC THERAPEUTICS INCPTCTHealth Care
PTC Therapeutics develops precision medicines and gene therapies targeting rare genetic disorders and serious diseases, generating revenue from approved…
$78.45 (as of 2026-07-23) · market cap $6.5B
-
Sarepta TherapeuticsSRPTHealth Care
A biopharmaceutical leader in genetic medicine, specializing in innovative RNA-targeted therapies and gene treatments for Duchenne muscular dystrophy and rare…
$15.88 (as of 2026-07-23) · market cap $1.6B
-
NOVARTIS AGNVS
Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases.
$156.14 (as of 2026-07-23) · market cap $228.8B
-
KRYSTAL BIOTECH INCKRYSHealth Care
Krystal Biotech is a genetic medicine company leveraging its proprietary HSV-1 vector platform to treat rare diseases, headlined by its FDA-approved topical…
$327.50 (as of 2026-07-23) · market cap $9.8B
-
EDITAS MEDICINE INCEDITHealth Care
A pioneering CRISPR gene editing company developing in vivo therapies for genetic diseases, with lead candidate EDIT-401 targeting hyperlipidemia through LDL…
$2.73 (as of 2026-07-23) · market cap $417M
-
BEAM THERAPEUTICS INCBEAMHealth Care
Beam Therapeutics is developing base editing medicines—a precision genetic cure approach—for serious inherited diseases like sickle cell disease and rare…
$25.91 (as of 2026-07-23) · market cap $2.7B
-
CAPRICOR THERAPEUTICS INCCAPRHealth Care
Capricor is a clinical-stage biotech developing cell and exosome therapies for rare genetic disorders, with its lead candidate Deramiocel under FDA review for…
$19.83 (as of 2026-07-23) · market cap $1.1B
Not quite? Describe exactly what you want →
Peers are ROCKET PHARMACEUTICALS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: ROCKET PHARMACEUTICALS INC (RCKT).
Last updated 2026-07-23.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.